Phase
Condition
Congestive Heart Failure
Chest Pain
Heart Failure
Treatment
N/AClinical Study ID
Ages > 21 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients of either gender who are greater than 21 years of age (no upper age limit),
Permission of patient's clinical attending physician,
Previous clinical diagnosis of HF with current New York Heart Association (NYHA)Class II-III symptoms for at least 1 month,
Left ventricular ejection fraction (EF) >50% by echocardiography, MRI, CT or x-rayor nuclear ventriculography within prior 12 months,
Stable medical therapy for at least 30 days (no addition or removal or major (>100%)dose change of Renin-Angiotensin-Aldosterone System (RAAS) antagonists,beta-blockers, or calcium channel blockers for hypertension).
Exclusion
Exclusion Criteria:
Unable to understand the risks, benefits, and alternatives of participation and givemeaningful consent,
Contraindications to MRI such as implanted metallic objects (pre-existing cardiacpacemakers, cerebral clips) or indwelling metallic projectiles,
Significant valvular abnormalities,
Pregnant women (women of childbearing potential will undergo blood or urinepregnancy testing),
History of clinical CAD or significant epicardial coronary disease (>50% stenosis)in major coronary artery by x-ray or CT angiography unless (a) the patient underwentprior successful revascularization with percutaneous coronary angioplasty within theprior three years and (b) there are no residual lesions of >50% on the most recentcoronary angiographic study.
History of infiltrative cardiomyopathy or constrictive pericarditis,
Cor pulmonale,
Significant pulmonary disease,
Estimated glomerular filtration rate (eGFR) <20ml/min,
Any condition other than HF which could limit the ability to perform a 6MW orcardiopulmonary exercise test (CPET) test (e.g., critical peripheral vasculardisease, significant orthopedic or neurological conditions),
Any diseases other than HF which are likely to significantly alter the patient'sglobal perception of status or quality of life over a period of 6 months.
Significant peripheral vascular disease
Study Design
Study Description
Connect with a study center
Johns Hopkins Hospital
Baltimore, Maryland 21287
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.